Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.785 EUR
−57.48 M EUR
5.29 M EUR
30.62 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Founded
2004
ISIN
CH0256379097
FIGI
BBG0079TC178
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange MOLECULAR PARTNERS SF 1 stocks are traded under the ticker 6ML.
We've gathered analysts' opinions on MOLECULAR PARTNERS SF 1 future price: according to them, 6ML price has a max estimate of 15.90 EUR and a min estimate of 6.36 EUR. Watch 6ML chart and read a more detailed MOLECULAR PARTNERS SF 1 stock forecast: see what analysts think of MOLECULAR PARTNERS SF 1 and suggest that you do with its stocks.
Yes, you can track MOLECULAR PARTNERS SF 1 financials in yearly and quarterly reports right on TradingView.
MOLECULAR PARTNERS SF 1 is going to release the next earnings report on Aug 25, 2025. Keep track of upcoming events with our Earnings Calendar.
6ML earnings for the last quarter are −0.47 EUR per share, whereas the estimation was −0.38 EUR resulting in a −25.00% surprise. The estimated earnings for the next quarter are −0.44 EUR per share. See more details about MOLECULAR PARTNERS SF 1 earnings.
MOLECULAR PARTNERS SF 1 revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
6ML net income for the last quarter is −17.51 M EUR, while the quarter before that showed −11.95 M EUR of net income which accounts for −46.58% change. Track more MOLECULAR PARTNERS SF 1 financial stats to get the full picture.
No, 6ML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 29, 2025, the company has 174 employees. See our rating of the largest employees — is MOLECULAR PARTNERS SF 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS SF 1 EBITDA is −61.80 M EUR, and current EBITDA margin is −1.18 K%. See more stats in MOLECULAR PARTNERS SF 1 financial statements.
Like other stocks, 6ML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS SF 1 stock right from TradingView charts — choose your broker and connect to your account.